Index

45 and Up Study, 104

absolute risk increase (ARI), 132–3
absolute risk reduction (ARR), 132–3
accuracy
assessing in measurement, 179
cause of death, 75
diagnostic tests, 336
of measurements, 172
screening tests, 329
see also precision
active surveillance, 268
acute laryngitis, and antibiotics, 246
administrative health systems, 68
adult mortality rates, 51
age
and body mass index (BMI), 146, 148
distributions, 50
age-specific rates, 43–4
age-standardised rates, 45–6, 50
agents of infection, see infectious agents
air pollution, and asthma, 149
airborne transmission, 289
alcohol, and lung cancer, 187–9, 190
alpha (α) errors, 147
alternative hypothesis, 147
American Institute of Cancer Research, 260
analogy, in evaluating causation, 241
analytic studies, 21, 93, 161, 173
antibiotics, and acute laryngitis, 246
ascertainment bias, 166
aspirin
and colorectal cancer, 238
and endocarditis, 40, 124
associations
aspects to consider, 238–42
between outcomes and exposure, 147
and chance, 147–8
in clinical epidemiology, 129
confounding, 192, 194
continuous measures, 139
looking for, 133
missed true, 151–3
strength of, 123, 151, 238
versus causation, 233–5
see also measures of association
asthma
and air pollution, 149
and body mass index (BMI), 216–17
and smoking, 32
atrial fibrillation, and statin use, 219
attack rates, 4, 36, 287
see also incidence proportion (IP)
attributable burden of disease, 315
attributable fractions (AF), 131–2, 136–7, 315
see also population attributable fractions (PAF)
attributable proportion, see attributable fractions (AF)
attributable risk percent, see attributable fractions (AF)
attributable risks (AR), see calculation, 131, 132
calculation, 131, 132
cautions regarding, 138
clinical epidemiology, 132
interpreting, 132–3
measures, 129–38
population, 133–4
strengths and uses, 139
versus relative risks, 138–9
Australian National Health Survey, 80
Australian Ovarian Cancer Study, 107
autism spectrum disorders, and flea treatment, 217
autonomy and ethics, 113
autopsies, verbal, 72
Avon Longitudinal Study of Parents and Children (UK), 103
background rates, 130
background risks, 130
Beecher’s Report, 114
Behavioral Risk Factor Surveillance System (BRFSS), 274
Belmont Report, 114
beneficence, 113
Berkeley’s bias, 166
β-carotene, 355–6
beta (β) errors, 147, 151–2
bias
when evaluating screening programs, 341–5
with hospital controls, 108
interviewer or observer, 110, 178
and misclassification, 173
see also specific types e.g. selection bias
bicycle helmets, and head injury, 137, 207
big data, 86–7
biases, 137, 207
Biosensor database, 289
biological plausibility, 240
BIOSIS database, 247
birth defects, and thalidomide, 107
birthweight, and breast cancer, 254–5
blood pressure, and cardiovascular disease, 309–10, 312
blood transfusion, and Creutzfeldt–Jakob disease (CJD), 214
body mass index (BMI)
and age, 146, 148
and asthma, 216–17
and diabetes, 313
and type-2 diabetes, 239–40
brain cancer, and mobile telephones, 254–5
breast cancer
and birthweight, 254–5
cases at Toowong ABC, 298
control of, 305, 306
screening for, 261, 330, 341–2, 343, 348
British Doctors Study, 15, 21, 102, 103, 138–9
burden of disease, 135, 267, 305, 314–16
Canadian Task Force on Preventive Health Care (CTFPHC), 250
cancer
disease registries, 75
standardised mortality ratios (SMRs), 84
see also specific types e.g. breast cancer
cancer epidemiology, 4
cardiovascular disease (CVD)
and blood pressure, 309–10, 312
and disability-adjusted life years (DALYs), 233–2
mortality rates, 319
risk factors, 307–8
© in this web service Cambridge University Press
www.cambridge.org
cardiovascular disease (CVD) (cont.)
standardised mortality ratios (SMR), 84
terms used, 45
see also ischaemic heart disease (IHD)
case–cohort studies, 105
case–control studies, 106–10
attributable fractions (AF), 136–7
and confounding, 187–9
control selection, 108
detection bias, 166
eligibility and exclusion criteria, 168
estimating incidence, 126
and hospital controls, 108–9
interviewer or observer bias, 110
low response rates, 163–4
matching, 198, 199
measurement errors, 173, 181
nested, 105, 106
odds ratios, 126–7
recall bias, 110
and screening programs, 347
selection bias, 161, 169
case–crossover studies, 110
case definitions, 29, 276, 292
case fatality rate (CFR), 50, 61
case-finding, 327
case-reference (or case-referent) studies, see case–control studies
case reports, 67
case series, 67
categorical data, 139
causal diagrams, see directed acyclic graphs (DAGs)
causal model for infectious diseases, 267
causal reasoning, 235
causation, 230
considering, 232
counterfactual (potential) outcomes model of, 236–7
definition, 230–1
evaluating, 235, 236, 238–42
evidence for outbreaks, 295–6
identifying, 16
models of, 231–2, 237
versus association, 233–5
cause of death
accuracy, 72, 75
coding, 70, 72, 73, 75
census data, 68
Centers for Disease Control and Prevention (CDC), 291
cervical cancer, 346, 347, 360
chance, 147–8, 220
chicken pox, 270
child mortality rates, 51
cholera, 12–14, 22–4, 233–5
cholesterol levels, and ischaemic heart disease (IHD), 310
cholera, 298
civil registration systems, 68, 70–1
clinical epidemiology, 5, 124, 128–9, 132
clinical significance, 155–6
versus statistical significance, 155–6
clinical trials, 40, 95, 162
see also randomised controlled trials (RCTs)
cluster randomised controlled trials, 99
clusters
definition, 284
historical, 297
investigation of, 297–8
non-infectious diseases, 296–9
and surveillance, 267
see also outbreaks
Cochrane Central Register of Controlled Trials, 247
Cochrane Collaboration, 219, 256, 360
coherence, in evaluating causation, 241
cohort studies, 100–3
case–cohort studies, 105
compared to randomised controlled trials, 101
and confounding, 192
definition, 36
historical, 103
loss to follow-up, 162, 166, 170
matching, 198
measurement errors, 173
notable examples, 101, 103
recall bias, 102
selection bias, 161
statin use, 219
colorectal cancer, and aspirin, 238
common-source outbreaks, 293
communicable diseases, see infectious diseases
communication of risk, 291
community trials, 99
competing causes, 36
complex systems, 362–3
component causes, 230, 232
conditional logistic regression, 202
confidence intervals described, 148–50
formulate, 377–8
and p-values, 150–1, 153
confidentiality, 87
confounders characteristics of, 189–90
determining, 192–5
confounding, 24
and associations, 192, 194
and case–control studies, 187–9
checking for in reports, 217–20
and cohort studies, 192
control by data analysis, 200–6
controlling by matching, 198–200
controlling by randomisation, 197
controlling by restriction, 197
controlling by stratification, 200–2
definition, 186
effects of, 190–2
by indication, 197, 219
multivariable modelling, 202–4
and population attributable fractions (PAF), 134
residual, 204
and size of studies, 200
and study design, 195–200
versus effect modification, 201
consistency, in evaluating causation, 238, 256
contamination, 99
continuous measures, 139, 173
contraception, oral
births versus harm, 308
and coronary heart disease (CHD), 192–4
and ovarian cancer, 125–6
and thromboembolism, 166
control event rate (CER), 40, 129
critical point in disease process, 327
counterfactual (potential) outcomes model of, 236–7
Cox proportional hazards regression, 287
creativity, 86
current data, 86
volume of, 86
see also health data

© in this web service Cambridge University Press

Cambridge University Press
978-1-108-76680-7 — Essential Epidemiology
4th Edition
Index

More Information
data linkage, 104–5, 168
death:
  competing causes, 36
  establishing cause of, 72, 73, 75
see also mortality rates
death registers, 71, 73
Declaration of Helsinki, 114
deduction, 235
demographic and health surveys, 68, 81
demographic surveillance systems, 68, 72
denominators, 32
density sampling, 127
depression risk factors, 217
descriptive epidemiology, 7, 35, 66, 359
descriptive statistics, 16
descriptive studies:
  assessing, 203–5
  by person, place and time, 7, 17–21, 292
  selection bias, 161
detection bias, 166
diabetes:
  and body mass index (BMI), 239–40, 313
  in China, 80
  gestational, 29
  and obesity, 140–1
trends in mortality, 74
diagnostic studies, 112
diagnostic tests:
  accuracy, 336
  compared to screening tests, 335
  predictive values, 336
  sensitivity, 336–9
  specificity, 336–9
diethylstilboestrol (DES) exposure, and vaginal cancer, 151
difference measures, 129–38
  differential misclassification, 175–6, 181, 215, 216
digital surveillance, 271–3
direct standardisation, 45, 50, 366–7
direct transmission, 289
directed acyclic graphs (DMGs), 190, 191, 195–6
disability-adjusted life years (DALYs), 2, 58–9, 232, 233
disability-free life expectancy, 55–6
diseases:
  attributable and avoidable burden, 314–16
  burden of, 135, 267, 305, 314–16
  control, 303, 305
  diagnosis, 28, 326, 329
  duration of, 34–5
  elimination of, 268
  endemic, 286
  measures of, 28–30
  natural history of, 16, 326
  notifiable, 41, 76
  process, 326–7
  prognosis, 16
  and screening, 328–9
  see also incidence; prevalence (P), prevention
disease registries, 68, 75–6
Doll, Sir Richard, 14, 21
dose–response relationships, 239–40
dynamic simulation modelling, 362
Ebola virus outbreak, 266, 267, 291
eco-epidemiology, 4
eco-epidemiology:
  ecological fallacy, 41, 86
  ecological studies, 54, 85–6, 113
  effect measures, see measures of association
effect modification, 201
  electronic medical records, 76
  eligibility criteria, 167
  endemic diseases, 286
  endocarditis, and aspirin, 40, 124
  epidemic curves, 13, 293, 294
  Epidemic Intelligence Service (EIS), 291
  epidemics:
  definition, 6–8, 284, 286
  point-or common-source, 293–4
  propagative, 293
  see also outbreaks
  epidemiology:
  definition, 2–3
  dimensions of, 16–21
  historical beginnings, 10–15
  purposes, 15–16
  role of, 2
  subdisciplines, 4–6
  errors:
  assessing effects of, 179–81
  control of, 178–9
  limiting, 357
  random, 171–2, 176, 180
  random sampling, 146–7, 161, 169
  sources of, 160–1, 177–8
  systematic, 161, 172–3, 175
  type I or alpha (α), 147
  type II or beta (β), 147, 151–2
  see also measurement errors
  Escherichia coli infection, 283
  ethics, 113–15, 152
  event-based surveillance, 268–9, 271–2
  event rates, 129
  see also incidence proportion (IP)
  evidence classification, 249, 256
  excess rates, 130
  excess risks, 130
  exchangeability, 121, 131
  exchangeable groups, 95, 96
  exclusion criteria, 167
  expected years of life lost (EYLL), 56
  experimental data, in evaluating causation, 241
  experimental event rate (EER), 40, 129
  external comparisons, to assess selection bias, 169
  external validity, 162, 222
  see also generalisability
  false negative test results, 330
  false positive test results, 330
  Farr, Williams, 11, 66, 233
  fetal death rates, 51, 52
  fetal death ratios, 51, 52
  feasibility study, 171
  feld treatment, and autism spectrum disorders, 217
  fluoridation, 99
  food frequency questionnaires, 174–5, 179
  force of morbidity, 38
  forest plots, 280
  Framingham Heart Study, 101–2
  funnel plots, 248
  Gapminder World, 81
  generalisability (external validity), 103, 112, 162, 222
  gestational diabetes, 29
  Global Cancer Observatory, 81
  global health indicators, 51–61
  Global Health Observatory, 81
  globalisity, 38
  Goldberger, Joseph, 14
  GRADE (Grading of Recommendations, Assessment, Development and Evaluation) criteria, 256
  Graham, Ewart, 14
  Graunt, John, 11
  H1N1 influenza virus, 284
  H5N1 avian influenza, 271
  haemolytic uraemic syndrome, 283
  harm from screening programs, 348, 349
  hazard ratios, 198, 202
  head injury, and bicycle helmets, 137, 207
  health-adjusted life expectancy (HALE), 2, 57–8
  health data:
  morbidity, 68, 75–8
  mortality, 68–72
  record linkage, 104–5, 168
  use of existing, 81–6
  health and demographic surveillance systems (HDSS), 68, 72
  health expectancy measures, 56
  health gap measures, 56
  health records, 68, 76–7, 104
  healthcare recorders, 268
  HealthMap, 273
  healthy worker effect, 163
  heart disease, and energy intake, 191, 192, 194, 196
  and vaginal cancer, 151
  and obesity, 140–1
Helicobacter pylori, and stomach cancer, 85–6, 113, 212, 240, 241–2
hepatitis A, and tomatoes, 296
hepatitis C, 289
hepatitis D, 289
hepatitis G, 289
hepatitis B, 289
hepatitis E, 289
heterogeneity, assessing, 250–1
Hill, Sir Austin Bradford, 14, 21, 236, 240
Hippocrates of Cos, 10, 113
historical cohort studies, 5, 102
HIV/AIDS
prevalence and incidence rates, 30–3
screening for, example, 332–5
hospital administrative systems, 68, 76, 77
hospital controls, 108–9
hosts of infection, 288
human papillomavirus (HPV) infection, 360
human research ethics guidelines, 114
Humme, David, 235
hypothesis tests, 147, 148, 153, 154
inception cohort, 105
incidence, 33
estimating, 126
and prevalence, 30–3
and treatments, 35
incidence density, as incidence rates (IR)
incidence proportion (IP), 36, 39–40, 61, 129
in clinical epidemiology, 129
in clinical trials, 40
and incidence rates, 37, 38
and lifetime risk, 47
versus incidence rate, 38
incidence rates (IR), 41
age-specific, 43–4
calculation, 34, 37, 42, 61
crude, 42–3
estimating, 135
formulae for standard deviation, 378
and incidence proportion (IP), 37, 38
and prevalence, 34–5
incident cases, 33
incubation periods, 288
indicator-based surveillance, 268, 270
Indigenous Australians, mortality rates, 17–18
indirect case–definition, 48, 50, 372–3
indirect transmission, 289
individual risk, versus population risk, 308–11
induction, in causation, 235
induction period, 327
infant mortality rates, 51, 53, 54
infection, 287
infectious agents, 287–8
hosts, 288
transmission, 288–9
infectious disease epidemiology, 4, 285
infectious diseases
causal model, 287
challenges of, 286
definition, 285
distribution, 283
and environmental factors, 290
and epidemiology, 285–6
zoonotic origins, 286
see also outbreaks
infecitivity, 287
infestation, 287
influenza immunisation rates, 124–5
infant mortality rates, 287
and child socioeconomic status (SES), 162
Institute for Health Metrics and Evaluation (IHME), 81
injury epidemiology, 4
injury risk, and child socioeconomic status (SES), 162
for treatment, 197, 342
interaction, see effect modification
intermediaries, 189
International Agency for Research on Cancer (IARC), 259–60
International Classification of Diseases, 70, 75
International Health Regulations (WHO), 271, 291
International Network for the Evaluation (INDEPTH), 72
International Studies of Infarct Survival, 96
interval case, 345
intervention studies, 21, 95–100, 162, 166
interventions
evaluating preventative, 319
evaluation, 16
preventive, 316–18
and surveillance, 267
interviewer bias, 110, 178
ischaemic heart disease (IHD)
age-specific mortality rates, 43
age-standardised rates, 45
and cholesterol levels, 310
crude mortality rates, 42, 43, 45
time trend, 370–1
mortality rates, 19
and sexual activity, 110
standardised mortality rates, 366–7
standardised mortality ratio (SMR), 372–3
and streptokinase, 153
terms used, 45
see also cardiovascular disease (CVD)
kidney disease, and phenacetin, 107
Koch, Robert, 285
Koch's postulates, 285
laryngitis, and antibiotics, 246
latent periods, 288, 327
lead time, 329, 341, 343
lead-time bias, 343, 344
Legionnaires disease, 290
length bias, 345
life expectancy, 54–5, 374
life table, 11, 55, 56, 374
life course epidemiology, 6, 94, 362
lifetime risk, 47, 370–1
likelihood ratio (LR) test, 339
literature
appraising, 249–50
searches, 247–8
logarithmic scale, 20, 251
longitudinal studies, see cohort studies
loss to follow-up, 41, 97, 103, 162, 166, 170
Louw, Pierre Charles-Alexandre (1877–1872), 11
low response rates, 163–5
lung cancer
age-standardised rates, 82–3
and alcohol, 187–9, 190
British Doctors Study, 15, 21, 102, 103, 138–9
control of, 305–6
luminal mortality ratios, 51
mammographic screening, 261, 330, 341–2, 343, 348
Mantel-Haenszel method for calculating pooled odds ratios, 379–80
mass gathering, surveillance, 273
matched odds ratios, 199
maternal mortality ratios, 51
measurement bias, 97, 171, 181, 215–17
measurement errors, 171–3
assessment of, 179–81
case-control studies, 181
checking for in reports, 215–17
control of, 178–9

effects of, 173–7
overview, 180
reducing, 358–9
sources of, 177–8
see also misclassification
measures of association
difference measures, 129–38
ratio measures, 123–9
measures of disease, 28–30
in practice, 35–41
summary of, 61
using routine data, 41–7
see also incidence: prevalence (P)
mediation analysis, 190
MEDLINE database, 247
Mendel, Gregor, 206
Mendelian randomisation (MR), 206
menopausal hormone therapy trial, 219
mesothelioma, 270
meta-analysis, 153, 252–3, 380
migrant studies, 84–5
Millennium Development Goals, 51, 52
Million Death Study, India, 72
miscategorisation, 102, 171
and bias, 173
differential, 175–6, 181, 215, 216
non-differential, 173–5, 181, 215, 217
mobile telephones
and brain cancer, 254–5
using for surveillance, 277
molecular epidemiology, 5
moral principles, 113
morbidity, force of, 38
morbidity data, 75–87
mortality, measures of, 41
mortality data, 68–72
challenges in using, 73–5
using, 42
mortality indicators, 51–4
mortality rates
and age-specific incidence, 43–4
age-standardised rates, 45–6
all-cause, 7, 42, 46–7
cardiovascular disease (CVD), 319
crude, 366
and crude incidence, 42–3
Indigenous Australians, 17–18
ischaemic heart disease (IHD), 42, 43, 45
lung cancer, 6, 83, 316
by person, place and time, 17–21
Russians, 7
standardised, 366–7
and standardised incidence, 45–6
trends in United States, 19–20, 74
tuberculosis (TB), 303–4
and veterans’ health, 164
mortality ratios
proportional, 50, 61
and standardised incidence, 48, 129
multiple logistic regression, 202
multivariable modelling, 202–4
n-of-1 trials, 98
narcolepsy in children, and influenza vaccination, 274
narrative reviews, 245
National Health and Nutrition Examination Surveys (NHANES), 79, 110
natural history of disease, 16
necessary causes, 198, 230
negative predictive values (NPV), 331–2
negative test results, true and false, 330
neonatal mortality rates, 51
nested case–control studies, 105, 106
non-communicable disease
reporting, 270
non-differential misclassification, 173–5, 181, 215, 217
non-infectious diseases, clusters, 296–9
non-maleficence, 113
non-randomised designs, 99, 346–8
non-responders, 165
notifiable disease systems, 68, 269
notifiable diseases, 41, 76
null hypothesis, 147
null values, 150
number needed to treat (NNT), 132
numerators, 32
Nuremberg Code, 113, 114, 115
Nurses’ Health Study (US), 21, 102
nutritional epidemiology, 4, 355
obesity, and type-2 diabetes, 140–1
observational studies, 100–13, 206, 212
observer bias, 110, 178
occupational epidemiology, 5
occupational studies, 50
odds, 126
odds ratios (OR)
approximating rate ratios, 127
approximating risk ratios, 127, 376
calculation, 125–7
case–control studies, 126–7
cross-sectional studies, 128
interpreting, 127
matched, 199
poled, 188, 379
using 2×2 tables, 188
oesophageal adenocarcinoma, and smoking, 214–15
outbreak
common-source, 293
definition, 284
evidence of causation, 295–6
hypothosis-generation and testing phase, 294–5
identification phase, 292–4
investigating steps, 291–2
management, 290–1
non-infectious diseases, 296–9
point-source, 293
propagative, 293
role of epidemiology, 284
and surveillance, 267
see also clusters
ovarian cancer, and oral contraceptive pill, 125–6
p-values, 147
and confidence intervals, 150–1, 153
interpreting, 152–5
reliance on, 154
and statistical significance, 152, 154
pandemics, 284
parallel group trials, 98
participants, 102, 106, 162–3
see also selection bias
passive surveillance, 268
pathogenicity, 287
phenylketonuria, screening for, 328
pharmacoepidemiology, 108, 109
pharmaceutical drugs, 268
person-years, 37
person-time measures, 37
placebo, 97
placebo effect, 97
placebo groups, 98
placebo, 97
point estimates, 148
point-of-1 trials, 98
point prevalence, 32
positive predictive values (PPV), 133–4
positive results, true and false, 330
population attributable fractions (PAF), 133
population attributable risk percent, 134
population attributable fractions (PAF), 134–5
population attributable risks (PAR), 134–5
interpreting, 135
strengths and uses, 139
population risk, versus individual risk, 308–11
populations
at risk, 34, 39
defining, 166
standard, 46, 50, 368
stationary, 35
study, 50, 77
target, 77
whole, 133
positive predictive values (PPV), 331–2, 340
positive test results, true and false, 330
post-test probability, 336
potential impact fraction (PIF), 315
potential years of life lost (PYLL), 56–7
power of studies, 146, 151–2
precision
assessing, 179
and confidence intervals, 148
poor, 171, 172
predictive values
diagnostic tests, 336
positive and negative, 331–2, 340
pressure bandages, and coronary angiography, 128–9, 132
pre-test probability, 336
prevalence (P)
calculation, 33, 34, 39, 61
definition, 32
and incidence, 30–3
and incidence rates, 30, 34
prevalence odds ratios (POR), 128
prevalence ratios, 123, 125
prevalence surveys, 77
prevalent cases, 108, 112
prevention
choosing strategy, 306
definition, 303
and epidemiology, 303, 305–7
evaluating interventions, 319
high-risk strategy, 311–12
interventions, 316–18
mass strategy, 312–13
‘middle-road’ strategy, 313
paradox, 320
and population attributable fractions (PAF), 314
population or individual level, 308–11
primary, 16, 303, 304
primoedal, 304
scope of, 307–8
secondary, 303, 325
tertiary, 303
preventive trials, 95, 97
primary prevention, 16, 303, 304
primordial prevention, 304
privacy laws, 114
probability values, see p-values
prognosis of disease, 16
prognostic studies, 108
Program for Monitoring Emerging Diseases (ProMED), 271
propagative outbreaks, 293
propensity scores, 205
proportional mortality ratios (PMR), 50, 61
proportions, 48
prospective studies, see cohort studies
PROSPERO register, 247
prostate cancer, screening for, 328
public health factors determining, 270
goals, 28
policy, 260–1
Public Health Emergency of International Concern (PHEIC), 271
public health epidemiology, 4
publication bias, 248
PubMed database, 247
quality-adjusted life year (QALY), 57
quantitative bias analysis, 171, 180
random errors, 171–2, 176, 180
random sampling errors, 146–7, 161, 169
random selection, 96
randomisation, 96, 197, 206
randomised controlled trials (RCTs) compared to cohort studies, 101
follow-up, 97
interpreting results, 219
and interventions, 197
and screening programs, 346
selection bias, 98
study design, 95–8
translation of results, 319
rate of disease assumption, 128
rate of change, 305
rate differences, 130–1
ratio measures, 123–9
rates, 48
rate ratios, 123, 127
rates, 48
target, 77
reading reports
assessing descriptive studies, 223
checking for confounding, 217–20
checking for measurement bias, 215–17
checking role of chance, 220
classification of selection bias, 213
identifying research question, 212
internal validity, 212–13, 220–1
interpreting results, 219, 221–2
questions to consider, 211, 215, 217
studies designs, 212
systematic approach, 211
see also systematic reviews
recall bias, 102, 110, 175, 177
receiver operating characteristic (ROC) curves, 339
record linkage, 104–5, 168
recorders, 268
recruitment of participants, see selection bias
reference groups, see control groups
reference rates, 130
reference tests, 112
regression analysis, 202
relative measures, 123–9
relative risk increase (RRI), 124, 129
relative risk reduction (RRR), 129
relative risks, 4
in clinical epidemiology, 128–9
and confidence intervals, 150
and null value, 150
strengths and uses, 139
use of term, 128
versus attributable risks, 138–9
see also risk ratios
relative survival rates, 50
reports
guidelines for results, 224
see also reading reports
research
ethics, 114, 152
translation into practice, 354–62
research questions, 212, 247
reservoirs of infection, 287
resilience to control confounding, 204
response rates, low, 165
restriction, to control confounding, 197
results
graphing, 250
guidelines for reporting, 224
interpreting in reports, 221–2
translating to real world, 319
retrospective cohort study, see historical cohort studies
reverse causality, 21, 102, 111
risk
formulae for standard deviation, 378
lifetime, 47, 370–1
outbreak assessment tools, 291
population versus individual, 308–11
populations at 34, 39
see also incidence proportion (IP)
risk differences, 130, 131
risk factors, 19, 59, 101
risk ratios, 123–5
odds ratio as approximate, 127, 376
rounding, 33, 126
rumour surveillance, 271
sample size, 151
sampling, 78
sampling error (random), 146–7
see also chance; sample size
SARS epidemic (2003), 50, 271, 286
screening, 325–50
aim of, 325–6
for bowel cancer, 329, 347
for breast cancer, 261, 330, 341–2, 343, 348

for cervical cancer, 346–7
critical point, 327
definition of, 325
and disease, 328–9
and epidemiology, 323
for HIV, 332–5
negative consequences, 348–9
for phenylketonuria, 328
for prostate cancer, 328
relationship to the disease process, 326–7
versus case-finding, 327
see also screening programs; screening tests
screening programs
disease suitability, 328–9
evaluating, 340–1
lead-time bias, 343, 344
length bias, 345
negative consequences, 348–9
potential sources of bias in evaluation, 341–5
requirements, 328–36, 338
study designs for evaluation, 345–8
test requirements, 329–30
volunteer bias, 341–2
screening tests
accuracy, 329
compared to diagnostic tests, 335
negative predictive values, 331–2
positive predictive values, 331–2, 340
requirements, 329–30
sensitivity, 329, 330–1
specificity, 329, 330–1
true and false negatives, 330
true and false positives, 330
scarcity, 93
secondary attack rate, 287
secondary prevention, 303, 325
see also screening
selection bias (systematic sampling error)
assessing effects of, 168–71
case–control studies, 161, 169
checking for in reports, 213
clinical trials, 162, 166
cohort studies, 161
control of, 166–8
cross-sectional studies, 111
definition, 161
descriptive studies, 161
evaluation of screening programs, 341–3
healthy worker effect, 163
and loss to follow-up, 162, 166
low response rates, 163–4
and random sampling errors, 146
randomised controlled trials (RCTs), 98
sources of, 162–6
sensitivity analysis for, 170
volunteer bias, 162–3
self-controlled case series, see case–crossover studies
sensitivity, of screening tests, 174, 329, 330–1, 332–8
sensitivity analysis, 170, 180, 213, 217
sentinel surveillance, 273
sexual activity, and myocardial infarction (heart attack), 110
shoe-leather epidemiology, 20
significance, see statistical significance
Simpson’s paradox, 186, 190
smallop, 20
smoking
and asthma, 32
and lung cancer, 14–15, 83, 138–9, 188, 190, 204, 233, 305–6, 316
doing oesophageal adenocarcinoma, 214–15
response rates, 165
and stroke incidence, 121–2, 130, 132, 133, 135
Snow, John, 12–14, 22–4
social epidemiology, 4, 94
socioeconomic status (SES), and child risk of injury, 162
specificity
as factor in evaluating causality, 240–1
of screening tests, 174, 329, 330–1, 336–8
standard populations, 46, 368
standardisation
direct, 45, 50, 366–7
indirect, 48, 50, 372–3
standardised incidence ratios (SIR), 48, 50, 61, 372–3
standardised mortality ratios (SMR), 18, 48, 50, 61, 84, 372–5
statin use, and atrial fibrillation, 219
stationary populations, 35
statistical significance, 147–8, 152, 154, 153–6
stepped-wedge design, 99
stillbirth rates, 51, 52
stillbirth ratios, 52
stomach cancer, and Helicobacter pylori, 85–6, 113, 212, 240, 241–2
stratification, to identity and control confounding, 188, 200–2
streptokinase, and heart attack mortality, 153
stroke incidence, and smoking, 121–2, 130, 132, 133, 135
study designs
case–control studies, 106–10, 168
case–crossover studies, 110
cohort studies, 100–3
control of confounding, 195–200
cross-sectional studies, 110–12
eligibility and exclusion criteria, 167
ideal, 94–5, 212
instrument choice, 178–9
intervention studies, 95–100
observational studies, 100–13
randomised controlled trials (RCTs), 95–8
screening program evaluation, 145–8
study populations, 50, 77
sudden infant death syndrome (SIDS) study, 107
sufficient causes, 230
suicide rates, 61, 111, 112, 203, 207–18
surveillance
active, 268
case definition, 276
definition, 267
digital, 271–3
epidemiology, 266
essentials, 275
event-based, 268–9, 271–2
indicator-based, 268, 270
key steps, 267
mass gathering, 273
passive, 268
rumour, 271
sentinel, 273
syndromic, 276
types of, 268–74
undercount, 275–6
using mobile telephones, 277
surveillance data
analysis, 276–8
collection, 276, 277
surveillance pyramid, 275
surveillance systems, 278
surveys, 77, 79
see also cross-sectional studies
survival curves, 55
survival rates, 50
survival studies, 105
Sustainable Development Goals, 16, 51, 52, 76
syndromic surveillance, 276
system science approach, 362, 363
systematic errors, 161, 172–3, 174–7
systematic reviews, 245–56
appraising literature, 249–50
assessing heterogeneity, 250–1
assessing quality of, 256
and bias, 254–5
conclusions, 256
graphical display of results, 250
guidelines for, 245–6, 257
literature searches, 247–8
meta-analysis, 252–3
pooled analysis, 253
PROSPERO register, 247
publication bias, 248
summarising the data, 250–6
specifying research question, 247
studies for inclusion, 248, 253
validity of, 257
writing, 246
Index

416

Type I errors, 147, 151
Type II errors, 147, 151–3
Type-2 diabetes
  and body mass index (BMI), 124, 126
  and obesity, 140–1
Temporality, as factor in evaluating causality, 238
Tertiary prevention, 303
Thai Cohort Study, 102
Thalidomide, and birth defects, 107, 297
Thromboembolism, and oral contraception, 166
Titanic Inquiry Project, 10, 202
Tomatoes, and hepatitis A, 296
Translation of research into practice, 354–5
  challenges, 356
  improving measurement, 358–9
  limiting error, 357
  phases, 354
  synthesis and integration, 360–2
  transmission of infection, 288–9
  true negative test results, 330
  true positive test results, 330
  tuberculosis (TB), mortality rates, 303–4
Tuskegee syphilis study, 114
Unemployment insurance, 164
Under-5 mortality rates, 51
  undercount, 275–6
United Nations, 291
United States
  all-cause mortality rates, 46–7
  trends in mortality rates, 19–20, 74
US Air Force Suicide Prevention Program, 317–18
US Community Guide, 259
US Physicians’ Health Study, 96
US Preventive Services Task Force (USPSTF), 250, 258–62, 328, 346
Vaginal cancer, and diethylstilboestrol (DES) exposure, 151, 260, 297
Validity
  external, 162, 222
  internal, 162, 212–13, 220–1
Vitamin A, and childhood mortality, 96
Vital statistics, 68–72
Volunteer bias, 162–3, 341–2
Women’s Health Initiative (WHI), 219
World Health Organization (WHO), 2, 46, 51, 56, 76, 266, 271, 277, 289, 291, 314
  Global Cancer Observatory, 81
  Global Health Observatory, 81, 83
  International Classification of Diseases, 70, 75
  writing papers, 223–4
Wynder, Ernest, 14
Years of life lost (YLL), 56–7
Zoonotic origins of infections, 286